Full Press Release Details
CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting. The TPD Summit will be held October 30–November 2 in Boston, Massachusetts, and CTOS will be held November 1–4 in Dublin, Ireland.
6th Annual Targeted Protein Degradation Summit
Foghorn will participate in multiple sessions, including a keynote presentation by Steve Bellon, Foghorn’s Chief Scientific Officer, where data from its selective EP300 and CBP degrader programs will be presented. Danette Daniels, Foghorn’s Vice President, Protein Degradation Platform, will provide the conference’s opening remarks as the Chair.
Presentation Details
Title: Advancement of Degraders Targeting Key Chromatin Regulators Involved in Disease/Oncology
Presenter: Steve Bellon, Chief Scientific Officer, Foghorn Therapeutics
Session: Keynote Plenary Session
Date: October 31, 2023
Title: Lay of the Land – What Does the Next 3 Years of TPD Drug Discovery & Development Look Like?
Presenter: Laura La Bonte, Senior Director, Biology & Research Portfolio Strategy, Foghorn Therapeutics
Session: Clinical Development
Date: October 31, 2023
Connective Tissue Oncology Society Annual Meeting
Presentation Details
Title: Preliminary results from a Phase 1 study of FHD-609, a bromodomain-containing protein 9 degrader, in patients with advanced synovial sarcoma or SMARCB1-loss tumors
Presenter: J. Andrew Livington, M.D., M.S., MD Anderson Cancer Center
Session: Session 4, Paper 25
Session date and time: November 2, 2023, 16:00-17:30 WET
Title: Pharmacodynamic and mechanistic impacts of FHD-609, A BRD9 degrader, in a Phase 1 study in patients with advanced synovial sarcoma or SMARCB1-loss tumors
Session date and time: November 2, 2023, 17:30-18:30 WET
Presenter: Mike Collins, Senior Scientist, Foghorn Therapeutics
About Foghorn Therapeutics
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
Greg Dearborn, Foghorn Therapeutics Inc. (Investors)
Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
Michael Lampe, ScientPR (Media)
Hans Vitzthum, LifeSci Advisors (Investors)